Tags

Type your tag names separated by a space and hit enter

Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment.
Clin Kidney J 2019; 12(2):294-299CK

Abstract

Background

A sub-analysis of a Phase III study was conducted to identify factors that might predict increased ferritin levels during long-term sucroferric oxyhydroxide (SO) treatment in hemodialysis patients.

Methods

The open-label, multicenter, Phase III study assessed the efficacy and safety of SO 750-3000 mg/day for 52 weeks in Japanese patients with chronic renal failure and hyperphosphatemia. A total of 125 of 161 patients from the Phase III trial, and who had data for ferritin levels after 28 weeks of SO treatment, were evaluated.

Results

Baseline ferritin was the strongest contributor (P < 0.0001) to ferritin increases during SO treatment. By Week 28, there were significant differences (P < 0.05/3) in ferritin increases between patients with higher [quartile 4 (Q4)] versus lower (Q1, Q2 and Q3) baseline ferritin. An erythropoiesis-stimulating agent dosage reduction was observed in patients with the lowest baseline ferritin level (Q1), and only slight reductions were noted in the other patient subsets. SO dosages administered to patients in baseline ferritin quartiles Q2, Q3 and Q4 were comparable throughout the study with slight fluctuations. SO dosages in Q1 were considerably lower than those in the other quartiles.

Conclusions

In summary, of the baseline variables found to predict increased ferritin, and changes in iron-related parameters, during SO treatment in Japanese chronic kidney disease patients undergoing hemodialysis, baseline ferritin was the most relevant variable.

Authors+Show Affiliations

Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30976411

Citation

Koiwa, Fumihiko, et al. "Evaluation of Changes in Ferritin Levels During Sucroferric Oxyhydroxide Treatment." Clinical Kidney Journal, vol. 12, no. 2, 2019, pp. 294-299.
Koiwa F, Yokoyama K, Fukagawa M, et al. Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment. Clin Kidney J. 2019;12(2):294-299.
Koiwa, F., Yokoyama, K., Fukagawa, M., & Akizawa, T. (2019). Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment. Clinical Kidney Journal, 12(2), pp. 294-299. doi:10.1093/ckj/sfy077.
Koiwa F, et al. Evaluation of Changes in Ferritin Levels During Sucroferric Oxyhydroxide Treatment. Clin Kidney J. 2019;12(2):294-299. PubMed PMID: 30976411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of changes in ferritin levels during sucroferric oxyhydroxide treatment. AU - Koiwa,Fumihiko, AU - Yokoyama,Keitaro, AU - Fukagawa,Masafumi, AU - Akizawa,Tadao, Y1 - 2018/09/19/ PY - 2018/03/28/received PY - 2019/4/13/entrez PY - 2019/4/13/pubmed PY - 2019/4/13/medline KW - dialysis KW - end-stage kidney disease KW - ferritin KW - phosphate binder KW - sucroferric oxyhydroxide SP - 294 EP - 299 JF - Clinical kidney journal JO - Clin Kidney J VL - 12 IS - 2 N2 - Background: A sub-analysis of a Phase III study was conducted to identify factors that might predict increased ferritin levels during long-term sucroferric oxyhydroxide (SO) treatment in hemodialysis patients. Methods: The open-label, multicenter, Phase III study assessed the efficacy and safety of SO 750-3000 mg/day for 52 weeks in Japanese patients with chronic renal failure and hyperphosphatemia. A total of 125 of 161 patients from the Phase III trial, and who had data for ferritin levels after 28 weeks of SO treatment, were evaluated. Results: Baseline ferritin was the strongest contributor (P < 0.0001) to ferritin increases during SO treatment. By Week 28, there were significant differences (P < 0.05/3) in ferritin increases between patients with higher [quartile 4 (Q4)] versus lower (Q1, Q2 and Q3) baseline ferritin. An erythropoiesis-stimulating agent dosage reduction was observed in patients with the lowest baseline ferritin level (Q1), and only slight reductions were noted in the other patient subsets. SO dosages administered to patients in baseline ferritin quartiles Q2, Q3 and Q4 were comparable throughout the study with slight fluctuations. SO dosages in Q1 were considerably lower than those in the other quartiles. Conclusions: In summary, of the baseline variables found to predict increased ferritin, and changes in iron-related parameters, during SO treatment in Japanese chronic kidney disease patients undergoing hemodialysis, baseline ferritin was the most relevant variable. SN - 2048-8505 UR - https://www.unboundmedicine.com/medline/citation/30976411/Evaluation_of_changes_in_ferritin_levels_during_sucroferric_oxyhydroxide_treatment L2 - https://academic.oup.com/ckj/article-lookup/doi/10.1093/ckj/sfy077 DB - PRIME DP - Unbound Medicine ER -